Aprea Therapeutics
APRE
39 hedge funds and large institutions have $591M invested in Aprea Therapeutics in 2019 Q4 according to their latest regulatory filings, with 39 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.08% more ownership
Funds ownership: 0% → 3.08% (+3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$62.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$59M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$49.9M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$40.5M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$19.9M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
New York State Common Retirement Fund
Albany,
New York
| $266K | +$160K | +290 | New |
|
|
CIM
27
Coastal Investment Management
Los Angeles,
California
| $229K | +$138K | +250 | New |
|
|
AIG
28
American International Group
New York
| $186K | +$111K | +202 | New |
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $108K | +$65.5K | +119 | New |
|
30
JP Morgan Chase
New York
| $97K | +$57.8K | +105 | New |
|
|
SO
31
STRS Ohio
Columbus,
Ohio
| $78K | +$46.8K | +85 | New |
|
32
Legal & General Group
London,
United Kingdom
| $59K | +$35.2K | +64 | New |
|
33
Citigroup
New York
| $59K | +$35.8K | +65 | New |
|
34
Bank of America
Charlotte,
North Carolina
| $50K | +$30.3K | +55 | New |
|
35
Bank of Montreal
Toronto,
Ontario, Canada
| $37K | +$22.6K | +41 | New |
|
|
AIP
36
Ameritas Investment Partners
Lincoln,
Nebraska
| $25K | +$15.4K | +28 | New |
|
37
Wells Fargo
San Francisco,
California
| $24K | +$14.3K | +26 | New |
|
|
WEC
38
Winslow Evans & Crocker
Boston,
Massachusetts
| $8K | +$4.41K | +8 | New |
|
39
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | +$3.85K | +7 | New |
|
APRE Hedge Fund Activity: Q4 2019 in Review
39 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q4 2019, worth a combined $591M.
Buyers outnumbered sellers: 39 funds opened new APRE positions and 0 closed out — a net gain of 39 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $62.5M.
- 39 institutional investors held Aprea Therapeutics (APRE) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $591M of Aprea Therapeutics stock for Q4 2019.
- 39 funds opened new Aprea Therapeutics positions in Q4 2019 and 0 closed out, a net change of +39 holders.
- The largest Aprea Therapeutics buyer in Q4 2019 was Redmile Group, an estimated $62.5M added.
Based on aggregated 13F filings for Q4 2019.